Drug Profile

Bimatoprost - SpyGlass Pharma

Latest Information Update: 11 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SpyGlass Pharma
Class Amides; Antiglaucomas; Lipids; Prostaglandins; Small molecules
Mechanism of Action Prostaglandin F2alpha receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Glaucoma; Ocular hypertension

Most Recent Events

02 Jun 2025 SpyGlass Pharma plans a two phase III registrational trial in Glaucoma in 2025 (Ophthalmic)
24 Apr 2025 Updated efficacy data from a phase I trial in Glaucoma and Ocular Hypertension released by SpyGlass Pharma
08 Apr 2025 SpyGlass anticipates commercial approval of bimatoprost from US FDA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com